Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ipilimumab, nivolumab and tocilizumab with SBRT in pretreated advanced pancreatic cancer
2019-004438-40Phase 2Terminated
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, nivolumab and tocilizumab in pancreatic cancer (PC) and pancreatic cancer (PDAC), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Objective response rate (ORR) in PART A LEAD-IN. Started Dec 2019; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2019-004438-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004438-40.